Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
322 stopped studies mapped to Chronic Leukemia and descendants · 84% state a reason
Over the 322 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic… | Phase 2 | withdrawn | Jan 25, 2016 | Fred Hutchinson Cancer Center | Low enrollment | Enrollment / accrual |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic… | Phase 1 / Phase 2 | withdrawn | Feb 9, 2016 | University of Michigan Rogel Cancer Center | FDA has placed all trials involving Pacritinib on Full Clinical Hold | Other (stated, no rule matched) |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00587457 | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic… | Phase 1 | terminated | Jan 7, 2008 | MedImmune LLC | The study is terminated early due to unavailability of investigational product. | Other (stated, no rule matched) |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Jul 4, 2007 | Genentech, Inc. | not stated | Not stated |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00708721 | Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic… | Phase 1 / Phase 2 | terminated | Jul 2, 2008 | University of Utah | Data analysis revealed sufficient data for safety and efficacy | Safety / toxicity |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell… | Phase 1 | terminated | Jun 4, 2012 | Tufts Medical Center | Unavailability of study article | Other (stated, no rule matched) |
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk… | Phase 1 | withdrawn | Sep 30, 2015 | Washington University School of Medicine | Lack of funding following full FDA clinical hold | Funding |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | Phase 2 | withdrawn | Feb 25, 2015 | University of California, San Diego | withdrawn | Other (stated, no rule matched) |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | Phase 2 | terminated | Aug 2, 2010 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
| NCT00596336 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application…(CLLIFVAC) | Phase 2 | terminated | Jan 17, 2008 | The Royal Bournemouth Hospital | Recruitment issues | Enrollment / accrual |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte… | Phase 2 | terminated | Aug 7, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02285244 | Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic… | Phase 2 | withdrawn | Nov 6, 2014 | James Blachly | Decision made by the Principal Investigator | Investigator |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH) | Phase 3 | terminated | Dec 13, 2012 | Hospital Israelita Albert Einstein | Lack of accrual | Enrollment / accrual |
| NCT02086591 | A Phase II Study of Doxycycline in Relapsed NHL | Phase 2 | terminated | Mar 13, 2014 | University of Rochester | Lack of accrual | Enrollment / accrual |
| NCT01600053 | Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | Phase 2 | terminated | May 16, 2012 | Thomas Kipps | interim analysis showed that the trial will not meet the interim endpoint. | Efficacy / futility |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | CTEP Initiated Action. | Other (stated, no rule matched) |
| NCT02147873 | Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | Phase 2 | terminated | May 28, 2014 | TetraLogic Pharmaceuticals | Study terminated due to lack of efficacy | Efficacy / futility |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic… | Phase 2 | terminated | Jan 18, 2006 | German CLL Study Group | slow recruitment | Enrollment / accrual |
| NCT00281931 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic… | Phase 2 | terminated | Jan 25, 2006 | German CLL Study Group | not stated | Not stated |
| NCT00416910 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic… | Phase 3 | terminated | Dec 28, 2006 | German CLL Study Group | low recruitment | Enrollment / accrual |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | Phase 2 | terminated | Oct 10, 2008 | Northwell Health | study suspended while data is reviewed for safety and efficacy. | Safety / toxicity |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Nov 3, 2014 | Mayo Clinic | not stated | Not stated |
| NCT02640833 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic… | Phase 1 | withdrawn | Dec 29, 2015 | AbbVie | Study Stopped | Other (stated, no rule matched) |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia… | Phase 2 | terminated | Jan 28, 2014 | Ångstrom Pharmaceuticals | Slow enrollment | Enrollment / accrual |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell… | N/A | terminated | Jul 25, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic…(NADIR) | — | terminated | Oct 24, 2014 | Astellas Pharma International B.V. | The study was terminated due to insufficient subject enrollment and very slow enrollment. | Enrollment / accrual |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia…(Rev-CLL) | Phase 2 | terminated | Sep 11, 2008 | University Health Network, Toronto | Seven years of follow-up \& final analysis done in Dec 2012. | Other (stated, no rule matched) |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | Phase 1 | terminated | Oct 12, 2007 | Dana-Farber Cancer Institute | lack of efficacy and tolerability | Efficacy / futility |
| NCT02556346 | Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose… | Phase 1 | withdrawn | Sep 22, 2015 | Molecular Templates, Inc. | The patient population (CLL \& SLL) was included in another ongoing study involving NHL patients. | Other (stated, no rule matched) |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells +…(TAIL) | Phase 1 | terminated | May 23, 2012 | Baylor College of Medicine | not stated | Not stated |
| NCT01510756 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Jan 16, 2012 | Thomas Kipps | slow enrollment | Enrollment / accrual |
| NCT00849524 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects… | Phase 2 | terminated | Feb 24, 2009 | Januario Castro, M.D. | drug supply became unavailable | Drug supply |
| NCT00942409 | Study of Repeat Intranodal Injections of Ad-ISF35 | Phase 2 | terminated | Jul 20, 2009 | Januario Castro, M.D. | drug supply was no longer available | Drug supply |
| NCT01010568 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | Nov 10, 2009 | Georgetown University | Unable to accrue patients due to change in standard CLL therapy | Enrollment / accrual |
| NCT01739491 | A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino… | — | withdrawn | Dec 3, 2012 | Janssen Pharmaceutica | The study is cancelled. FDA Circular 2013-004 mandates that PMSs like this are not required | Other (stated, no rule matched) |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT01076556 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell… | Phase 1 | terminated | Feb 26, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01126502 | Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic… | Phase 1 | terminated | May 19, 2010 | National Cancer Institute (NCI) | Administratively Complete. | Other (stated, no rule matched) |
| NCT00924040 | Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The supply of BL22 has expired and MedImmune the sponsor is not interested in producing any new… | Drug supply |
| NCT02258555 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With… | Phase 1 | terminated | Oct 7, 2014 | Gilead Sciences | not stated | Not stated |
| NCT00587847 | Campath Maintenance in Chronic Lymphocytic Leukemia | N/A | terminated | Jan 8, 2008 | Northwell Health | Insufficient recruitment. | Enrollment / accrual |
| NCT00391066 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in…(LUCID) | Phase 2 | terminated | Oct 23, 2006 | Biogen | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 27, 2017source: clinicaltrials